摘要:
Compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51, R6, R13 and R20 has the meanings indicated in the description, are novel active bronchial therapeutics.
摘要:
The compounds of formula (I) in which R1, R2, R3, R4, R5, X and Y have the meanings as given in the description are novel effective bronchial therapeutica.
摘要:
The invention concerns the compounds 8,9-Diethoxy-2-methyl-6- [4(p-toluenesulfonamido)phenyl] -1,2,3,4,4a,10b-hexahydrobenzo[c] [1,6]naphthyridine and 9-Ethoxy-8-methoxy-2- methyl-6-[4-(p-toluenesulfonamido) phenyl]-1,2,3,4,4a,10b-hexahydrobenzo [c][1,6]naphthyridine and their therapeutic application.
摘要:
Compounds of formula (I) in which R4 is a phenyl radical substituted by R5, where R5 is a tetrazole-5-yl radical optionally substituted by a radical R6, are novel efficacious PDE3/4 inhibitors.
摘要:
The invention concerns compounds of formula (I) in which the substituents and symbols have the meanings given in the description. These compounds are advantageous resistance modulators.
摘要:
Les dihydropyridines de formule (I), dans laquelle les substituants et les symboles ont la signification indiquée dans la description, sont de nouvelles substances possédant des propriétés pharmacologiques intéressantes.
摘要:
The N-oxides of the compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings indicated in the description, are novel active bronchial therapeutics.
摘要:
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4 and Y have the meanings given in the description. Said compounds are novel active bronchial therapeutic agents.
摘要:
Compounds having the formula (I), in which R1, R2, R3, R4 and n have the meanings given in the description, are new effective bronchotherapeutic agents (phosphodiesterase IV inhibitors).